COVID-19 vaccine candidate shows early promiseNew data from a phase 1/2 clinical trial of a vaccine candidate being developed by Pfizer and German biopharmaceutical company BioNTech show the vaccine produced a robust immune response and was tolerable in healthy adults.
The results appeared today in Nature.The trial, which involved 45 healthy volunteers aged 18 to 55, compared different dose levels of BNT162b1, a nucleoside-modified messenger RNA (mRNA) vaccine that encodes the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.
Twelve participants per dose level (10 μg and 30 μg) were vaccinated on days 1 and 21, and 12 volunteers received a 100-μg dose on day 1.